Tag Archive for: Phase 1

Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy

Orally administered treatment was well tolerated, with early signs of clinical activity In models of non-proliferative diabetic retinopathy (NPDR), danegaptide has demonstrated protection against retinal capillary loss and vascular leakage Data support continued advancement into Phase 2 clinical evaluation Copenhagen, Denmark, 24 June 2025 – Breye Therapeutics ApS (Breye), a clinical-stage ophthalmology focused biopharmaceutical company […]

Domain Therapeutics Presents Novel Data Addressing Key Challenges in Oncology at AACR 2025

Phase I clinical results of DT-9081, an EP4 receptor antagonist, allowed selection of recommended Phase II dose (RP2D) for further development in solid tumors Preclinical data of DT-7012 position this Treg depleting anti-CCR8 antibody as a highly differentiated candidate for clinical development Preclinical findings demonstrate high potential of the PAR2 biased negative allosteric modulator (NAM) […]

iOnctura reaches new clinical milestones in uveal melanoma

Completed Phase I DIONE-01 study demonstrates clinical activity and long-term safety of roginolisib, a unique allosteric modulator of PI3Kδ Patients with uveal melanoma showed a doubling of overall survival compared to historical controls Site activation ongoing for randomized Phase II OCULE-01 study in uveal melanoma Geneva, Switzerland and Amsterdam, The Netherlands, 11 Dec 2024 – […]

Vicebio Advances Clinical Study of RSV/hMPV Bivalent Vaccine & Strengthens Board with Appointments of World Class Veterans

Vicebio enters the second stage of its Phase 1 Clinical Study of its lead candidate VXB-241  The Clinical Study, an actively controlled Proof of Concept Phase 1 conducted in target population aged 60+, is progressing as planned with initial data expected by mid-2025 Moncef Slaoui, former Chief Scientific Advisor of Operation Warp Speed & former […]

STORM Therapeutics Presents New Clinical Data on its First-in-Class METTL3 Inhibitor STC-15 at SITC 2024

STC-15 is well tolerated and demonstrates promising signs of clinical activity observed in multiple tumor types Gene expression data shows upregulation of innate immunity pathways Tumor regressions observed at all dose levels, 60-200 mg TIW 11 November 2024, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat […]